SMT201300116B - Procedimenti e intermedi per la preparazione di uninibitore macrociclico di proteasi di hcv - Google Patents

Procedimenti e intermedi per la preparazione di uninibitore macrociclico di proteasi di hcv

Info

Publication number
SMT201300116B
SMT201300116B SM201300116T SM201300116T SMT201300116B SM T201300116 B SMT201300116 B SM T201300116B SM 201300116 T SM201300116 T SM 201300116T SM 201300116 T SM201300116 T SM 201300116T SM T201300116 B SMT201300116 B SM T201300116B
Authority
SM
San Marino
Prior art keywords
intermediates
preparation
hcv
procedures
protease inhibitor
Prior art date
Application number
SM201300116T
Other languages
English (en)
Italian (it)
Inventor
Andras Horvath
Dominic John Ormerod
Dominique Paul Michel Depre
Veronique Cerpentier
Original Assignee
Janssen Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceuticals Inc filed Critical Janssen Pharmaceuticals Inc
Publication of SMT201300116B publication Critical patent/SMT201300116B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/12—Preparation of carboxylic acid amides by reactions not involving the formation of carboxamide groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/40—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00—Preparation of carboxylic acid esters
    • C07C67/475—Preparation of carboxylic acid esters by splitting of carbon-to-carbon bonds and redistribution, e.g. disproportionation or migration of groups between different molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/32—Oxygen atoms
    • C07D307/33—Oxygen atoms in position 2, the oxygen atom being in its keto or unsubstituted enol form
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C07D453/04—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems having a quinolyl-4, a substituted quinolyl-4 or a alkylenedioxy-quinolyl-4 radical linked through only one carbon atom, attached in position 2, e.g. quinine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
  • Furan Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
SM201300116T 2008-12-23 2013-10-10 Procedimenti e intermedi per la preparazione di uninibitore macrociclico di proteasi di hcv SMT201300116B (it)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08172691 2008-12-23
PCT/EP2009/067715 WO2010072742A1 (en) 2008-12-23 2009-12-22 Processes and intermediates for preparing a macrocyclic protease inhibitor of hcv

Publications (1)

Publication Number Publication Date
SMT201300116B true SMT201300116B (it) 2013-11-08

Family

ID=40548041

Family Applications (1)

Application Number Title Priority Date Filing Date
SM201300116T SMT201300116B (it) 2008-12-23 2013-10-10 Procedimenti e intermedi per la preparazione di uninibitore macrociclico di proteasi di hcv

Country Status (22)

Country Link
US (2) US8927722B2 (enExample)
EP (1) EP2382198B1 (enExample)
JP (1) JP5687631B2 (enExample)
KR (1) KR101734507B1 (enExample)
CN (1) CN102264715B (enExample)
AR (1) AR074863A1 (enExample)
AU (1) AU2009331530B2 (enExample)
BR (1) BRPI0923393B1 (enExample)
CA (1) CA2745565C (enExample)
CY (1) CY1114488T1 (enExample)
DK (1) DK2382198T3 (enExample)
ES (1) ES2429013T3 (enExample)
HR (1) HRP20130906T1 (enExample)
IL (1) IL213246A (enExample)
MX (1) MX2011006764A (enExample)
PL (1) PL2382198T3 (enExample)
PT (1) PT2382198E (enExample)
RU (1) RU2016120007A (enExample)
SI (1) SI2382198T1 (enExample)
SM (1) SMT201300116B (enExample)
TW (1) TWI461424B (enExample)
WO (1) WO2010072742A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2382198T3 (da) 2008-12-23 2013-09-30 Janssen Pharmaceuticals Inc Fremgangsmåder og mellemprodukter til fremstilling af en makrocyklisk inhibitor af hcv-protease
TWI565704B (zh) 2011-09-22 2017-01-11 健生醫藥公司 用於製備hcv巨環蛋白酶抑制劑之方法及中間物
JP6231482B2 (ja) 2011-10-28 2017-11-15 ヤンセン ファーマシューティカルズ,インコーポレーテッド 大環状プロテアーゼ阻害剤tmc435の中間体の改善された製造方法
CN103387509B (zh) * 2012-05-11 2016-06-08 重庆博腾制药科技股份有限公司 一种hcv蛋白酶抑制剂中间体的制备方法
IN2014MN02652A (enExample) 2012-06-08 2015-08-21 Gilead Sciences Inc
AR091279A1 (es) * 2012-06-08 2015-01-21 Gilead Sciences Inc Inhibidores macrociclicos de virus flaviviridae
SI2859009T1 (sl) * 2012-06-08 2017-12-29 Gilead Sciences, Inc. Makrociklični inhibitorji flaviviridae virusov
UA119315C2 (uk) 2012-07-03 2019-06-10 Гіліад Фармассет Елелсі Інгібітори вірусу гепатиту с
JP6511432B2 (ja) 2013-03-15 2019-05-15 ギリアード サイエンシーズ, インコーポレイテッド C型肝炎ウイルスの大環状二環式阻害剤
CN105308043B (zh) * 2014-05-29 2018-01-30 杭州普晒医药科技有限公司 丙型肝炎药物的晶型及其制备方法、其药物组合物和用途
MA41812A (fr) 2015-03-27 2018-01-30 Janssen Pharmaceuticals Inc Procédés et intermédiaires pour la préparation d'un inhibiteur de protéase macrocyclique du vhc

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL8300536A (nl) 1983-02-14 1984-09-03 Oce Andeno Bv Optisch actief alfa-azido-p-hydroxyfenylazijnzuur en zijn zouten alsmede de bereiding daarvan.
JPS6124539A (ja) 1984-07-11 1986-02-03 Sagami Chem Res Center 光学活性(r)−2,5,12−トリヒドロキシ−1,2,3,4−テトラヒドロナフタセン−6,11−ジオン−2−カルボン酸の取得方法
JP4218040B2 (ja) 1997-12-26 2009-02-04 曽田香料株式会社 有機酸とアミンの複合塩の製造法
JP3844112B2 (ja) 2000-08-23 2006-11-08 高砂香料工業株式会社 3,5,6−トリヒドロキシヘキサン酸アンモニウム塩誘導体、及びその製造方法
ES2336009T3 (es) 2004-01-30 2010-04-07 Medivir Ab Inhibidores de la ns-3 serina proteasa del vhc.
CN101146806A (zh) 2005-01-21 2008-03-19 阿斯泰克斯治疗有限公司 用于抑制cdk和gsk的吡唑衍生物
EP1919904B1 (en) * 2005-07-29 2014-01-08 Janssen R&D Ireland Macrocyclic inhibitors of hepatitis c virus
PE20070211A1 (es) 2005-07-29 2007-05-12 Medivir Ab Compuestos macrociclicos como inhibidores del virus de hepatitis c
RU2483067C2 (ru) * 2007-02-01 2013-05-27 Тиботек Фармасьютикалз Лтд. Способы и промежуточные продукты для получения макроциклического ингибитора протеазы вируса гепатита с
MX2009008541A (es) * 2007-02-08 2009-08-18 Tibotec Pharm Ltd Fenilcarbamatos macrociclicos que inhiben el virus de hepatitis c.
DK2382198T3 (da) 2008-12-23 2013-09-30 Janssen Pharmaceuticals Inc Fremgangsmåder og mellemprodukter til fremstilling af en makrocyklisk inhibitor af hcv-protease

Also Published As

Publication number Publication date
KR20110099048A (ko) 2011-09-05
MX2011006764A (es) 2011-08-03
CA2745565C (en) 2017-03-07
US20110257403A1 (en) 2011-10-20
EP2382198A1 (en) 2011-11-02
DK2382198T3 (da) 2013-09-30
CN102264715A (zh) 2011-11-30
TW201033205A (en) 2010-09-16
RU2016120007A (ru) 2018-11-13
SI2382198T1 (sl) 2013-11-29
JP2012513381A (ja) 2012-06-14
BRPI0923393B1 (pt) 2018-06-19
IL213246A0 (en) 2011-07-31
US20150080577A1 (en) 2015-03-19
BRPI0923393A2 (pt) 2015-07-28
PL2382198T3 (pl) 2013-11-29
AU2009331530B2 (en) 2015-04-09
AU2009331530A1 (en) 2011-06-23
US8927722B2 (en) 2015-01-06
PT2382198E (pt) 2013-10-01
WO2010072742A1 (en) 2010-07-01
HRP20130906T1 (hr) 2013-10-25
EP2382198B1 (en) 2013-07-10
AR074863A1 (es) 2011-02-16
CA2745565A1 (en) 2010-07-01
CN102264715B (zh) 2015-12-02
CY1114488T1 (el) 2016-10-05
KR101734507B1 (ko) 2017-05-11
HK1164839A1 (zh) 2012-09-28
ES2429013T3 (es) 2013-11-12
IL213246A (en) 2017-10-31
JP5687631B2 (ja) 2015-03-18
RU2011130895A (ru) 2013-01-27
TWI461424B (zh) 2014-11-21
US9115077B2 (en) 2015-08-25

Similar Documents

Publication Publication Date Title
MX2011006764A (es) Procedimiento y compuestos intermedios para preparar un inhibidor de proteasa macrociclico del vhc.
HUS1700039I1 (hu) Makrociklusos prolinból leszármaztatható HCV szerin proteáz inhibitorok
NI201100170A (es) Inhibidores de epoxicetonas proteasa de tripéptidos cristalinos
MX2011011272A (es) Procesos e intermediarios.
WO2010111436A3 (en) Antiviral compounds and uses thereof
WO2012136383A8 (en) Preparation of sitagliptin intermediates
EA201270280A1 (ru) Соединения пиримидина в качестве ингибиторов при лечении туберкулеза
UA111827C2 (uk) Спосіб отримання інгенол-3-ангелату
AP2757A (en) Process for preparation of HIV protease inhibitors
EP2245015A4 (en) DIFLUORATED TRIPEPTIDES AS INHIBITORS OF HCV SERINE PROTEASE
MY155330A (en) Methods for salt production
WO2012137180A3 (en) Biomarkers of immunotherapy efficacy
UA106886C2 (uk) Спосіб одержання 1-бензил-3-гідроксиметил-1h-індазолу і його похідних та проміжні сполуки магнію
EP2291079A4 (en) FORMULATIONS FOR CATHEPSIN K HEMMER
BRPI0822347A2 (pt) método de produção de proteínas ou peptídeos heterólogos.
WO2010059916A3 (en) Preparation of docetaxel
ITRM20080037A1 (it) Procedimento per la ultrapurificazione di alginati.
CL2014001043A1 (es) Procedimiento para preparar un compuesto intermediario en la ruta de sintesis de tmc 435, inhibidor de proteasa, útil en el tratamiento de la hepatitis c.
IT1397023B1 (it) Composizioni comprendenti amminoacidi, per il trattamento della broncopneumopatia cronica ostruttiva
EA200870236A1 (ru) Моногидрат римонабанта, способ его получения и фармацевтические композиции на его основе
IL211266A (en) Process for adding thiols to alpha, beta-unsaturated beta compounds of sulfonyl or sulfonyl
EA201270223A1 (ru) ЭНАНТИО- И СТЕРЕОСПЕЦИФИЧЕСКИЕ СИНТЕЗЫ β-АМИНО-α-ГИДРОКСИАМИДОВ
EA201101652A1 (ru) Антиоомицеты
ITMI20060489A1 (it) Procedimento per la preparazione di 1-beono-3-trifluorometossibenzene
MX2013007359A (es) Inhibidores de hepatitis c y usos de los mismos.